About this trial
The investigators recently engineered a novel biomarker discovery approach that is non-destructive and fully compatible with OMICS profiling as well as routine clinical procedures (5). The latter approach - termed EXPEL - mines the interstitial tissue fluid that is the richest source of soluble, undiluted and uncontaminated biomarkers. The method notably gives access to proteins, metabolites, RNA, DNA and exosomes, thus enabling holistic biomarker discovery. Owing to its non-destructive nature, EXPEL provides for the first time both clinicians and researchers with the opportunity to analyze identical material.
The investigators hypothesize that the conservation liquid used to collect cells and biopsy after endoscopic ultrasound for pancreatic biopsy could contain the tissue secretome and permit a comprehensive OMICS analysis of PDAC (all stages confounded) by using a "modified EXPEL" procedure. These are ideal conditions for EXPEL approach that will additionally to finding novel biomarkers also shed light on complex network of cancer cell-stroma interactions.
Eligibility criteria
Qualifiers
Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy or surgery
Patient ≥18 years old
Patient naïve of any treatment of Pancreatic cancer
Disqualifiers
Patient who reject the study protocol
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
University Hospital, Montpellier
Lead sponsor
IRCM U1194 INSERM, Tumor Microenvironment and Resistance to Treatment Lab
Collaborator
IRCM U1194 INSERM, Cancer Bioinformatics and Systems Biology's team
Collaborator